Cargando…

Activation of Natural Killer T Cells by α-Galactosylceramide Rapidly Induces the Full Maturation of Dendritic Cells In Vivo and Thereby Acts as an Adjuvant for Combined CD4 and CD8 T Cell Immunity to a Coadministered Protein

The maturation of dendritic cells (DCs) allows these antigen-presenting cells to initiate immunity. We pursued this concept in situ by studying the adjuvant action of α-galactosylceramide (αGalCer) in mice. A single i.v. injection of glycolipid induced the full maturation of splenic DCs, beginning w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fujii, Shin-ichiro, Shimizu, Kanako, Smith, Caroline, Bonifaz, Laura, Steinman, Ralph M.
Formato:	Texto
Lenguaje:	English
Publicado:	The Rockefeller University Press 2003
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2194082/ https://www.ncbi.nlm.nih.gov/pubmed/12874260 http://dx.doi.org/10.1084/jem.20030324

Ejemplares similares

Cross-presentation of glycolipid from tumor cells loaded with α-galactosylceramide leads to potent and long-lived T cell–mediated immunity via dendritic cells
por: Shimizu, Kanako, et al.
Publicado: (2007)

Influenza Virus–induced Dendritic Cell Maturation Is Associated with the Induction of Strong T Cell Immunity to a Coadministered, Normally Nonimmunogenic Protein
por: Brimnes, Marie K., et al.
Publicado: (2003)

Natural Killer Dendritic Cells Enhance Immune Responses Elicited by α-Galactosylceramide-Stimulated Natural Killer T Cells
por: Lee, Sung Won, et al.
Publicado: (2013)

CD1d-Invariant Natural Killer T Cell-Based Cancer Immunotherapy: α-Galactosylceramide and Beyond
por: King, Lisa A., et al.
Publicado: (2018)

Corrigendum: CD1d-Invariant Natural Killer T Cell-Based Cancer Immunotherapy: α-Galactosylceramide and Beyond
por: King, Lisa A., et al.
Publicado: (2018)

CD1d-mediated Recognition of an α-Galactosylceramide by Natural Killer T Cells Is Highly Conserved through Mammalian Evolution
por: Brossay, Laurent, et al.
Publicado: (1998)

The Linkage of Innate to Adaptive Immunity via Maturing Dendritic Cells In Vivo Requires CD40 Ligation in Addition to Antigen Presentation and CD80/86 Costimulation
por: Fujii, Shin-ichiro, et al.
Publicado: (2004)

In vivo dendritic cell targeting cellular vaccine induces CD4(+) Tfh cell-dependent antibody against influenza virus
por: Yamasaki, Satoru, et al.
Publicado: (2016)

Suppression of murine tumour growth through CD8(+) cytotoxic T lymphocytes via activated DEC‐205(+) dendritic cells by sequential administration of α‐galactosylceramide in vivo
por: Kogo, Hideki, et al.
Publicado: (2017)

Cancer immunotherapy using artificial adjuvant vector cells to deliver NY‐ESO‐1 antigen to dendritic cells in situ
por: Fujii, Shin‐ichiro, et al.
Publicado: (2022)

Natural Killer T and Natural Killer Cell-Based Immunotherapy Strategies Targeting Cancer
por: Iyoda, Tomonori, et al.
Publicado: (2023)

Caveolin-1 Expression Increases upon Maturation in Dendritic Cells and Promotes Their Migration to Lymph Nodes Thereby Favoring the Induction of CD8(+) T Cell Responses
por: Oyarce, Cesar, et al.
Publicado: (2017)

α‐galactosylceramide generates lung regulatory T cells through the activated natural killer T cells in mice
por: Chen, Qianhui, et al.
Publicado: (2018)

Expansion of Lung Vα14 NKT Cells by Administration of α‐Galactosylceramide‐pulsed Dendritic Cells
por: Akutsu, Yasunori, et al.
Publicado: (2002)

Identification of distinct human invariant natural killer T-cell response phenotypes to alpha-galactosylceramide
por: Croudace, Joanne E, et al.
Publicado: (2008)

Dendritic cell maturation by innate lymphocytes: coordinated stimulation of innate and adaptive immunity
por: Münz, Christian, et al.
Publicado: (2005)

In Vivo Targeting of Antigens to Maturing Dendritic Cells via the DEC-205 Receptor Improves T Cell Vaccination
por: Bonifaz, Laura C., et al.
Publicado: (2004)

The Natural Killer T (NKT) Cell Ligand α-Galactosylceramide Demonstrates Its Immunopotentiating Effect by Inducing Interleukin (IL)-12 Production by Dendritic Cells and IL-12 Receptor Expression on NKT Cells
por: Kitamura, Hidemitsu, et al.
Publicado: (1999)

Immunotherapy with artificial adjuvant vector cells: Harnessing both arms of the immune response
por: Fujii, Shin-ichiro, et al.
Publicado: (2013)

Exploiting Antitumor Immunotherapeutic Novel Strategies by Deciphering the Cross Talk between Invariant NKT Cells and Dendritic Cells
por: Fujii, Shin-ichiro, et al.
Publicado: (2017)

Alpha-Galactosylceramide/CD1d-Antibody Fusion Proteins Redirect Invariant Natural Killer T Cell Immunity to Solid Tumors and Promote Prolonged Therapeutic Responses
por: Zhang, Lianjun, et al.
Publicado: (2017)

Natural Killer T Cell Ligand α-Galactosylceramide Enhances Protective Immunity Induced by Malaria Vaccines
por: Gonzalez-Aseguinolaza, Gloria, et al.
Publicado: (2002)

Direct Expansion of Functional CD25(+) CD4(+) Regulatory T Cells by Antigen-processing Dendritic Cells
por: Yamazaki, Sayuri, et al.
Publicado: (2003)

Targeted Co-delivery of Tumor Antigen and α-Galactosylceramide to CD141(+) Dendritic Cells Induces a Potent Tumor Antigen-Specific Human CD8(+) T Cell Response in Human Immune System Mice
por: Huang, Jing, et al.
Publicado: (2020)

Natural Killer T Cell Ligand α‐Galactosylceramide Inhibited Lymph Node Metastasis of Highly Metastatic Melanoma Cells
por: Nakui, Minoru, et al.
Publicado: (1999)

Dendritic Cells Cross-Present Latency Gene Products from Epstein-Barr Virus–Transformed B Cells and Expand Tumor-Reactive Cd8(+) Killer T Cells
por: Subklewe, Marion, et al.
Publicado: (2001)

CD11c(lo)B220(+) interferon-producing killer dendritic cells are activated natural killer cells
por: Vosshenrich, Christian A.J., et al.
Publicado: (2007)

Exogenous Activation of Invariant Natural Killer T Cells by α-Galactosylceramide Reduces Pneumococcal Outgrowth and Dissemination Postinfluenza
por: Barthelemy, Adeline, et al.
Publicado: (2016)

Dendritic cells require a systemic type I interferon response to mature and induce CD4(+) Th1 immunity with poly IC as adjuvant
por: Longhi, M. Paula, et al.
Publicado: (2009)

Structure and binding kinetics of three different human CD1d–α-galactosylceramide–specific T cell receptors
por: Gadola, Stephan D., et al.
Publicado: (2006)

Dendritic Cells as Adjuvants for Immune-mediated Resistance to Tumors
por: Schuler, G., et al.
Publicado: (1997)

Linking CD11b(+) Dendritic Cells and Natural Killer T Cells to Plaque Inflammation in Atherosclerosis
por: Rombouts, Miche, et al.
Publicado: (2016)

Defective NKT Cell Activation by CD1d+ TRAMP Prostate Tumor Cells Is Corrected by Interleukin-12 with alpha-Galactosylceramide
por: Nowak, Michael, et al.
Publicado: (2010)

CD8(+) T Cells Mediate CD40-independent Maturation of Dendritic Cells In Vivo
por: Ruedl, Christiane, et al.
Publicado: (1999)

Enhancement of Mucosal Immunogenicity of Viral Vectored Vaccines by the NKT Cell Agonist Alpha-Galactosylceramide as Adjuvant
por: Singh, Shailbala, et al.
Publicado: (2014)

CD25(+) CD4(+) T Cells, Expanded with Dendritic Cells Presenting a Single Autoantigenic Peptide, Suppress Autoimmune Diabetes
por: Tarbell, Kristin V., et al.
Publicado: (2004)

Efficient Targeting of Protein Antigen to the Dendritic Cell Receptor DEC-205 in the Steady State Leads to Antigen Presentation on Major Histocompatibility Complex Class I Products and Peripheral CD8(+) T Cell Tolerance
por: Bonifaz, Laura, et al.
Publicado: (2002)

Natural Killer Cells Regulate the Maturation of Liver Sinusoidal Endothelial Cells Thereby Promoting Intrahepatic T‐Cell Responses in a Mouse Model
por: Du, Yanqin, et al.
Publicado: (2021)

Expansion of invariant natural killer T cells from systemic lupus erythematosus patients by alpha-Galactosylceramide and IL-15
por: Hsu, Chien-Ya, et al.
Publicado: (2021)

Dendritic cell–expanded, islet-specific CD4(+) CD25(+) CD62L(+) regulatory T cells restore normoglycemia in diabetic NOD mice
por: Tarbell, Kristin V., et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_fnum6c312q9knask2dj6h88rt5